Crinetics Pharmaceuticals (CRNX) Stock Forecast & Price Target

Compare

709 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CRNX Analyst Ratings

Strong Buy

15 Buy

1 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Crinetics

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CRNX Stock 12 Month Forecast

Average Price Target

$80.60

▲(91.63% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Crinetics Pharmaceuticals in the last 3 months. The average price target is $80.60 with a high forecast of $143.00 and a low forecast of $40.00. The average price target represents a 91.63% change from the last price of $42.06.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","85":"$85","144":"$144","55.5":"$55.5","114.5":"$114.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$143.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$80.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,55.5,85,114.5,144],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,41.61,49.40923076923077,57.208461538461535,65.00769230769231,72.80692307692308,80.60615384615384,88.40538461538462,96.20461538461538,104.00384615384615,111.80307692307693,119.60230769230769,127.40153846153846,135.20076923076925,{"y":143,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,41.61,44.60923076923077,47.60846153846154,50.607692307692304,53.606923076923074,56.606153846153845,59.60538461538461,62.60461538461538,65.60384615384615,68.60307692307691,71.60230769230769,74.60153846153845,77.60076923076923,{"y":80.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,41.61,41.48615384615385,41.362307692307695,41.238461538461536,41.114615384615384,40.99076923076923,40.86692307692308,40.74307692307692,40.61923076923077,40.495384615384616,40.371538461538464,40.247692307692304,40.12384615384615,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":51.92,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.69,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.39,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.13,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.78,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.62,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.88,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.43,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.84,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.61,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$143.00

Average Price Target$80.60

Lowest Price Target$40.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Douglas Tsao

H.C. Wainwright

$81

Buy

92.58%

Upside

Reiterated

10/28/25

Crinetics Pharmaceuticals: Promising PFS Data and Strategic Focus Justify Buy RatingValuation and Risks. Our price target of $81 for Crinetics is based on 5.5x and our discounted 2035 risk- adjusted revenue estimate of $1.5B. We adjust each indication for probability of success with paltusotine at 90% for acromegaly, 70% for NETs, and atumelnant (ACTH inhibitor) for Cushing's disease at 50% for congenital adrenal hyperplasia (CAH) at 50%.

Yasmeen Rahimi

Piper Sandler

$97

Buy

130.62%

Upside

Reiterated

10/27/25

Crinetics Pharmaceuticals (CRNX) Receives a Buy from Piper Sandler

Cory Jubinville, PhD

LifeSci Capital

$92

Buy

118.74%

Upside

Reiterated

10/24/25

Promising Phase 3 Data and Strong Financial Position Justify Buy Rating for Crinetics PharmaceuticalsSociety (NANETS) Symposium, Crinecs (Nasdaq: CRNX) presented three posters highlighng its neuroendocrine tumor (NET) pipeline, which consists of paltusone, currently in Phase 3 for carcinoid syndrome (CS) associated with a nonpepde drug conjugate in development for neuroendocrine neoplasms (NEN). Of these three posters, one speciﬁcally caught our a enon, as it relates to preliminary progression free survival of paltusone in NETs, a hallmark endpoint for oncologic disease. The dataset provided an encouraging early look at one of the key remaining quesons surrounding paltusone in the CS seng, as the absence of PFS data is viewed by some as a potenal limitaon to broader adopon in paen ts with GEP-NETs.

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

10/23/25

Positive Long-Term Growth Outlook for Crinetics Pharmaceuticals Amid Palsonify ApprovalWe updated our CRNX model in conjunction with TD Cowen Biotech's Q3:25 earnings preview. We increased our peak Palsonify sales estimates following the September 25th approval by increasing our price/year. However, we slightly decreased our Palsonify 2025 revenue estimate, while increasing 2025 expenses leading to updated 2025 GAAP EPS of ($4.75) from ($4.40).

Joshua Schimmer

Cantor Fitzgerald

$90

Buy

113.98%

Upside

Reiterated

10/01/25

Crinetics Pharmaceuticals (CRNX) Gets a Buy from Cantor Fitzgerald

Leland Gershell

Oppenheimer

$73→$87

Buy

106.85%

Upside

Reiterated

09/30/25

Crinetics price target raised to $87 from $73 at OppenheimerCrinetics price target raised to $87 from $73 at Oppenheimer

Joseph Schwartz

Leerink Partners

$80→$88

Buy

109.22%

Upside

Reiterated

09/29/25

Analysts Are Bullish on Top Healthcare Stocks: Avidity Biosciences (RNA), Crinetics Pharmaceuticals (CRNX)

Alex Thompson CFA

Stifel Nicolaus

$58→$75

Buy

78.32%

Upside

Reiterated

09/29/25

Stifel Nicolaus Sticks to Their Buy Rating for Crinetics Pharmaceuticals (CRNX)

Maxwell Skor

Morgan Stanley

$65→$77

Buy

83.07%

Upside

Reiterated

09/29/25

Morgan Stanley Keeps Their Buy Rating on Crinetics Pharmaceuticals (CRNX)Morgan Stanley analyst Jeffrey Hung raised the price target on Crinetics (NASDAQ: CRNX) to $77.00 (from $65.00) while maintaining a Overweight rating.

Richard Law CFA

Goldman Sachs

$35→$40

Hold

-4.90%

Downside

Reiterated

09/29/25

Goldman Sachs Reaffirms Their Hold Rating on Crinetics Pharmaceuticals (CRNX)

Unknown Analyst

Evercore ISI

Not Ranked

Evercore ISI

$72→$80

Buy

90.20%

Upside

Reiterated

09/29/25

Crinetics Pharmaceuticals (CRNX) Gets a Buy from Evercore ISI

Jonathan Wolleben

Citizens JMP

$86→$143

Buy

239.99%

Upside

Reiterated

09/26/25

Crinetics price target raised to $143 from $86 at Citizens JMPCrinetics price target raised to $143 from $86 at Citizens JMP

Catherine Novack

JonesTrading

$65→$85

Buy

102.09%

Upside

Reiterated

09/26/25

Crinetics Pharmaceuticals (CRNX) Gets a Buy from JonesTradingJones Trading analyst Catherine Novack raised the price target on Crinetics (NASDAQ: CRNX) to $85.00 (from $65.00) while maintaining a Buy rating.

Brian Skorney

Robert W. Baird

$58→$62

Buy

47.41%

Upside

Reiterated

09/26/25

Robert W. Baird Keeps Their Buy Rating on Crinetics Pharmaceuticals (CRNX)Baird analyst Brian Skorney raised the price target on Crinetics (NASDAQ: CRNX) to $62.00 (from $58.00) while maintaining a Outperform rating.

Jessica Fye

J.P. Morgan

$53→$52

Buy

23.63%

Upside

Reiterated

09/24/25

Crinetics price target lowered to $52 from $53 at JPMorganCrinetics price target lowered to $52 from $53 at JPMorgan

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Douglas Tsao

H.C. Wainwright

$81

Buy

92.58%

Upside

Reiterated

10/28/25

Yasmeen Rahimi

Piper Sandler

$97

Buy

130.62%

Upside

Reiterated

10/27/25

Crinetics Pharmaceuticals (CRNX) Receives a Buy from Piper Sandler

Cory Jubinville, PhD

LifeSci Capital

$92

Buy

118.74%

Upside

Reiterated

10/24/25

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

10/23/25

Joshua Schimmer

Cantor Fitzgerald

$90

Buy

113.98%

Upside

Reiterated

10/01/25

Crinetics Pharmaceuticals (CRNX) Gets a Buy from Cantor Fitzgerald

Leland Gershell

Oppenheimer

$73→$87

Buy

106.85%

Upside

Reiterated

09/30/25

Crinetics price target raised to $87 from $73 at OppenheimerCrinetics price target raised to $87 from $73 at Oppenheimer

Joseph Schwartz

Leerink Partners

$80→$88

Buy

109.22%

Upside

Reiterated

09/29/25

Analysts Are Bullish on Top Healthcare Stocks: Avidity Biosciences (RNA), Crinetics Pharmaceuticals (CRNX)

Alex Thompson CFA

Stifel Nicolaus

$58→$75

Buy

78.32%

Upside

Reiterated

09/29/25

Stifel Nicolaus Sticks to Their Buy Rating for Crinetics Pharmaceuticals (CRNX)

Maxwell Skor

Morgan Stanley

$65→$77

Buy

83.07%

Upside

Reiterated

09/29/25

Richard Law CFA

Goldman Sachs

$35→$40

Hold

-4.90%

Downside

Reiterated

09/29/25

Goldman Sachs Reaffirms Their Hold Rating on Crinetics Pharmaceuticals (CRNX)

Unknown Analyst

Evercore ISI

Not Ranked

Evercore ISI

$72→$80

Buy

90.20%

Upside

Reiterated

09/29/25

Crinetics Pharmaceuticals (CRNX) Gets a Buy from Evercore ISI

Jonathan Wolleben

Citizens JMP

$86→$143

Buy

239.99%

Upside

Reiterated

09/26/25

Crinetics price target raised to $143 from $86 at Citizens JMPCrinetics price target raised to $143 from $86 at Citizens JMP

Catherine Novack

JonesTrading

$65→$85

Buy

102.09%

Upside

Reiterated

09/26/25

Brian Skorney

Robert W. Baird

$58→$62

Buy

47.41%

Upside

Reiterated

09/26/25

Jessica Fye

J.P. Morgan

$53→$52

Buy

23.63%

Upside

Reiterated

09/24/25

Crinetics price target lowered to $52 from $53 at JPMorganCrinetics price target lowered to $52 from $53 at JPMorgan

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Crinetics Pharmaceuticals

1 Month

xxx

Success Rate

8/14 ratings generated profit

Average Return

+8.71%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of +8.71% per trade.

3 Months

xxx

Success Rate

10/14 ratings generated profit

Average Return

+18.40%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +18.40% per trade.

1 Year

Douglas TsaoH.C. Wainwright

Success Rate

16/23 ratings generated profit

Average Return

+39.09%

reiterated a buy rating 2 days ago

Copying Douglas Tsao's trades and holding each position for 1 Year would result in 69.57% of your transactions generating a profit, with an average return of +39.09% per trade.

2 Years

xxx

Success Rate

26/32 ratings generated profit

Average Return

+64.87%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 81.25% of your transactions generating a profit, with an average return of +64.87% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRNX Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CRNX has received 29 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. CRNX average Analyst price target in the past 3 months is 80.60.

Each month's total comprises the sum of three months' worth of ratings.

CRNX Financial Forecast

CRNX Earnings Forecast

Next quarter’s earnings estimate for CRNX is -$1.24 with a range of -$1.44 to -$1.00. The previous quarter’s EPS was -$1.23. CRNX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year CRNX has Preformed in-line its overall industry.

CRNX Sales Forecast

Next quarter’s sales forecast for CRNX is $430.00K with a range of $0.00 to $2.70M. The previous quarter’s sales results were $1.03M. CRNX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year CRNX has Preformed in-line its overall industry.

CRNX Stock Forecast FAQ

What is CRNX’s average 12-month price target, according to analysts?

Based on analyst ratings, Crinetics Pharmaceuticals’s 12-month average price target is 80.60.

What is CRNX’s upside potential, based on the analysts’ average price target?

Crinetics Pharmaceuticals has 91.63% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CRNX a Buy, Sell or Hold?

Crinetics Pharmaceuticals has a consensus rating of Strong Buy which is based on 15 buy ratings, 1 hold ratings and 0 sell ratings.

What is Crinetics Pharmaceuticals’s price target?

The average price target for Crinetics Pharmaceuticals is 80.60. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $143.00 ,the lowest forecast is $40.00. The average price target represents 91.63% Increase from the current price of $42.06.

What do analysts say about Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of CRNX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Crinetics Pharmaceuticals (CRNX) Stock Forecast & Price Target

CRNX Analyst Ratings

CRNX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Crinetics Pharmaceuticals

CRNX Analyst Recommendation Trends

CRNX Financial Forecast

CRNX Earnings Forecast

CRNX Sales Forecast

CRNX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts